MSN and lymphangioleiomyomatosis: The elevated expression of moesin was subsequently validated in serum samples from patients with LAM compared with healthy control subjects and patients with OCLDs, suggesting that moesin could emerge as a new biomarker to help differentiate LAM from OCLDs and healthy subjects.